Latest Sales Growth News

AVADA Group reported a 14.9% rise in cash receipts for Q1 2026, underpinned by strong sales in Queensland and New South Wales, while completing a refinancing that improves liquidity and covenant headroom.

OMG Group posted a 44% increase in Q3 FY26 net sales, hitting a $6 million annual turnover milestone, while launching a dual matcha brand platform and securing national Woolworths distribution for new oat milk protein flavours.

Carma Limited surged past prior year sales with 1,344 units sold, boosted by rapid network expansion and improved reconditioning efficiency, while maintaining a solid cash position.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

HITIQ Limited's March quarter saw a remarkable 223% jump in sales to $294k, driven by the nationwide rollout of its PROTEQT™ concussion management system and initial international sales. The company bolstered its governance and advisory ranks while managing funding to support its commercial push.

Mirvac Group reported robust operational results in 3Q26, driven by a 28% jump in residential sales, high occupancy across its investment portfolio, and a successful $630 million capital raise for its wholesale office fund. The company reaffirmed its FY26 guidance amid cautious risk management.

Scentre Group has initiated a tender offer to repurchase all of its US$1.312 billion Non-Call 2030 Subordinated Notes, aiming to refinance this debt through existing senior bank facilities. The move follows recent capital management efforts and sets the stage for updated debt metrics.

Scentre Group’s first-quarter update reveals robust sales and visitation gains, near-full occupancy, and steady capital management moves, underpinning its confidence in 2026 earnings growth despite geopolitical uncertainties.

Scentre Group's first quarter update reveals robust retail sales growth and strong leasing metrics, alongside significant capital management moves including bond redemption and a major joint venture stake sale.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.